Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1635jxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	PDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	PAPPA enhanced with new search field, simultaneous left and

right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:50:45 ON 30 MAY 2003

=> s (collapsin (n) respons? (n) mediato? (n) protein (2n) 2) (n) (toad (n) 64) or ulip2 or (drp (n) 2)
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FIL MEDLINE BIOSIS EMBASE CA SCISEARCH
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.84 0.84

FILE 'MEDLINE' ENTERED AT 13:53:23 ON 30 MAY 2003

FILE 'BIOSIS' ENTERED AT 13:53:23 ON 30 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:53:23 ON 30 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CA' ENTERED AT 13:53:23 ON 30 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 13:53:23 ON 30 MAY 2003
COPYRIGHT 2003 THOMSON ISI

=> s (collapsin (n) respons? (n) mediato? (n) protein (2n) 2) (n) (toad (n) 64) or ulip2 or (drp (n) 2)
L1 83 (COLLAPSIN (N) RESPONS? (N) MEDIATO? (N) PROTEIN (2N) 2) (N) (TOAD (N) 64) OR ULIP2 OR (DRP (N) 2)

=> s antisense? or (anti (n) sense) or (compleme? (2n) (oligonucl? or nucleo?))
L2 121708 ANTISENSE? OR (ANTI (N) SENSE) OR (COMPLEME? (2N) (OLIGONUCL? OR NUCLEO?))

```
=> s l1 and l2
L3            2 L1 AND L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4            2 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 1-4 ibib abs

L4   ANSWER 1 OF 2  CA  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         137:246071  CA
TITLE:                    Gene expression profiles relating to normal and
                          osteoarthritic cartilage
INVENTOR(S):              Liew, Choong-Chin; Marshall, Wayne E.; Zhang, Hongwei
PATENT ASSIGNEE(S):       Chondrogene Inc., Can.
SOURCE:                   PCT Int. Appl., 777 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
     WO 2002070737      A2    20020912       WO 2002-CA247     20020228
     WO 2002070737      C1    20021031
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                  US 2001-271955P   P  20010228
                                        US 2001-275017P   P  20010312
                                        US 2001-305340P   P  20010713
AB   The invention provides gene expression profiles comprising one or more
     polynucleotide sequences that are expressed in chondrocytes from any of
     the following developmental and disease stages: fetus, normal adult, mild
     osteoarthritis, moderate osteoarthritis, marked osteoarthritis, and severe
     osteoarthritis. Complementary DNA libraries were constructed from human
     fetal, normal, mild osteoarthritic and severe osteoarthritic cartilage
     samples (13,398, 17,151, 12,651, and 14,222 expressed sequence tags
     (ESTs), resp.). The known and novel clones derived from these libraries
     were then used to construct human chondrocyte-specific microarrays to
     generate differential gene expression profiles useful as a diagnostic
     tools for detection of osteoarthritis. A total of 5807 expressed gene
     sequences are provided and matched to known gene sequences, other ESTs, or
     mitochondrial, ribosomal, vector, and cDNA/hypothetical protein sequences
     in the public databases. Arrays of the invention are useful as a gold
     std. for osteoarthritis diagnosis and for use to identify and monitor
     therapeutic efficacy of new drug targets.

L4   ANSWER 2 OF 2  CA  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         137:206517  CA
TITLE:                    Use of Ulip-and/or Ulip2 in the treatment of
                          myelin disorders
INVENTOR(S):              Aguera, Michelle; Belin, Marie-Francoise; Charrier,
                          Emmanuelle; Honorat, Jerome; Ricard, Damien; Fogemond,
```

Veronique
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002119944	A1	20020829	US 2001-986632	20011109

PRIORITY APPLN. INFO.: US 2000-246751P P 20001109

AB This invention relates to methods and compns. for the prevention or treatment of myelin disorders which involve modulating of Ulip/CRMP activity. In particular, a method for the prevention or treatment of myelin disorders is provided which comprises administering to a patient in need of such treatment a therapeutically effective amt. of an agent which modulates Ulip/CRMP activity, and which can be a Ulip/CRMP protein, a nucleic acid coding for a Ulip/CRMP protein, an **anti-sense** sequence capable of specifically hybridizing with said nucleic acid, an antibody directed against the Ulip/CRMP protein, or an aptamer capable of binding said protein, and a pharmacol. acceptable carrier.

=> d his

(FILE 'HOME' ENTERED AT 13:50:45 ON 30 MAY 2003)

FILE 'MEDLINE, BIOSIS, EMBASE, CA, SCISEARCH' ENTERED AT 13:53:23 ON 30 MAY 2003

L1 83 S (COLLAPSIN (N) RESPONS? (N) MEDIATO? (N) PROTEIN (2N) 2) (N)
L2 121708 S ANTISENSE? OR (ANTI (N) SENSE) OR (COMPLEME? (2N) (OLIGONUCL?
L3 2 S L1 AND L2
L4 2 DUP REM L3 (0 DUPLICATES REMOVED)

(FILE 'HOME' ENTERED AT 13:50:45 ON 30 MAY 2003)

FILE 'MEDLINE, BIOSIS, EMBASE, CA, SCISEARCH' ENTERED AT 13:53:23 ON 30 MAY 2003

L1 83 S (COLLAPSIN (N) RESPONS? (N) MEDIATO? (N) PROTEIN (2N) 2) (N)
L2 121708 S ANTISENSE? OR (ANTI (N) SENSE) OR (COMPLEME? (2N) (OLIGONUCL?
L3 2 S L1 AND L2
L4 2 DUP REM L3 (0 DUPLICATES REMOVED)

=> s l1 (5n) inhib?
L5 8 L1 (5N) INHIB?

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6 3 DUP REM L5 (5 DUPLICATES REMOVED)

=> d l6 1-3 ibib abs

L6 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1984:358102 BIOSIS
DOCUMENT NUMBER: BA78:94582
TITLE: INTERACTIONS BETWEEN KETAMINE AND PHENCYCLIDINE AND DORSAL ROOT POTENTIALS EVOKED FROM THE RAPHE NUCLEI.
AUTHOR(S): LARSON A A
CORPORATE SOURCE: DEP. VET. BIOLOGY, UNIV. MINN., 295 ANIMAL SCIENCE/VETERINARY MED. BUILDING, ST PAUL, MN 55108, USA.
SOURCE: NEUROPHARMACOLOGY, (1984) 23 (7 PART A), 785-792.
CODEN: NEPHBW. ISSN: 0028-3908.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB Dorsal root potentials (DRP) apparently to reflect presynaptic inhibition of primary afferent activity. Electrical stimulation of sites near the nucleus raphe magnus evokes 2 such potentials (DRP-1 and DRP-2) along dorsal roots of the lumbar and sacral spinal cord in the anemically decerebrated cat. DRP-2 is apparently serotonergically mediated, while the neurochemical mediator of DRP-1 is not known. Serotonin antagonists selectively **inhibit DRP-2** while the shorter latency DRP-1, which can elicited anywhere in the brain stem, is potentiated by these drugs. Most general anesthetics, such as ether or barbiturates, uniformly depressed both DRP-1 and -2. The dissociative anesthetics, ketamine and phencyclidine seemed to selectively **inhibit DRP-2**. This **inhibitory** effect of ketamine was dose-related, such that a dose of 11 mg/kg completely blocked DRP-2, but had no effect on DRP-1. Time-course studies indicated that the effect of phencyclidine on DRP-2 lasted much longer than that of ketamine. The effect of dissociative anesthetics on the descending pathways is unique compared to that of other anesthetic agents and their effect correlates well in time-course and dose-range to their sedative/anesthetic effects.

L6 ANSWER 2 OF 3 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 81144826 MEDLINE
DOCUMENT NUMBER: 81144826 PubMed ID: 6110778
TITLE: Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
AUTHOR: Larson A A; Chinn C; Proudfit H K; Anderson E G
CONTRACT NUMBER: NS-12649 (NINDS)
SOURCE: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1981 Apr) 217 (1) 99-104.
Journal code: 0376362. ISSN: 0022-3565.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198105
ENTRY DATE: Entered STN: 19900316
Last Updated on STN: 19970203
Entered Medline: 19810526

AB A variety of drugs reported to antagonize serotonin were found to affect spinal cord potentials evoked by electrical stimulation of the caudal raphe nuclei of the cat. These brain stem-evoked dorsal root potentials (DRPs) consisted of a short latency depolarization (DRP-1), which was evoked by stimulation of a wide variety of sites in the medial brain stem and a long latency potential (DRP-2), which was elicited only when stimuli were applied near the raphe. The ability of serotonergic antagonists to increase or decrease these DRPs was dependent on the dose of the drug administered. High doses of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL), methysergide and cinanserin each produced an immediate **inhibition** of **DRP -2** and a simultaneous enhancement of DRP-1, both of which recovered by approximately 30 min. Each of the drugs produced a dose-related **inhibition** of **DRP-2** at high doses, with LSD being the most potent and cinanserin the least potent. In contrast, low doses of LSD, BOL and methysergide elicited little or no immediate change in either DRP-2 or DRP-1, but produced an enhancement of DRP-2 which developed slowly over a period of 60 to 90 min. This increase in DRP-2 was most dramatic after administration of LSD and was not accompanied by changes in DRP-1. The **inhibition** of **DRP -2** by high doses of LSD, BOL, methysergide and cinanserin may result primarily from inhibition of postsynaptic serotonergic receptors located on the primary afferent terminals. The increase in DRP-2 produced by low doses of LSD, BOL and methysergide is postulated to result from an interaction with receptors distinct from those which produced the **inhibition** of **DRP-2** at higher doses.

L6 ANSWER 3 OF 3 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 80243485 MEDLINE
DOCUMENT NUMBER: 80243485 PubMed ID: 6249439
TITLE: The role of GABA and serotonin in the mediation of raphe-evoked spinal cord dorsal root potentials.
AUTHOR: Proudfit H K; Larson A A; Anderson E G
SOURCE: BRAIN RESEARCH, (1980 Aug 11) 195 (1) 149-65.
Journal code: 0045503. ISSN: 0006-8993.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198010
ENTRY DATE: Entered STN: 19900315
Last Updated on STN: 19900315
Entered Medline: 19801021

AB The possible involvement of bulbospinal serotonergic systems in the mediation of analgesia has created a need for a better understanding of the influence this system has on neuronal mechanisms in the spinal cord. Therefore, these studies were designed to examine the effects of caudal raphe stimulation on primary afferent depolarization and to determine the role of serotonin (5-HT) and GABA in the mediation of these stimulation-produced effects. Stimulation of the raphe evoked two electrotonically conducted dorsal root potentials (DRP-1 and DRP-2) and two compound action potentials (VRP-1 and VRP-2) which were recorded from the dorsal and ventral roots, respectively. Length constant measurements indicated that DRP-1 was generated in group II and DRP-2 in group I

primary afferent fibers. Histological determination of stimulation sites revealed that short-latency potentials (DRP-1 and VRP-1) were evoked from many sites within the caudal brain stem, while the long-latency potentials (DRP-2 and VRP-2) were evoked primarily from sites within the caudal raphe nuclei. The role of serotonin in mediating these evoked potentials was assessed by administering various antagonists of serotonin (cinanserin, methysergide and D-lysergic acid diethylamide). These agents consistently attenuated the long-latency potentials (DRP-2 and VRP-2) but increased the magnitude of DRP-1. The possibility of a GABAergic neuron in the descending systems projecting to primary afferent terminals was studied. Depletion of GABA by semicarbazide blocked DRP-1, but had only a modest effect of DRP-2. However, the putative GABA antagonist, bicuculline, **inhibited** both DRP-1, and **DRP-2**. These results suggest that a GABA interneuron is not involved in the bulbospinal serotonergic depolarization of primary afferent terminals. This system appears to constitute a presynaptic filter of afferent input, with the capacity to inhibit different fiber groups.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.48	47.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.24	-1.24

STN INTERNATIONAL LOGOFF AT 14:01:30 ON 30 MAY 2003